A COX-2 inhibitor, Etoricoxib is used in the treatment of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, spondylitis, chronic low back pain, and gout. It is a selective inhibitor of isoform 2 of the enzyme cyclooxygenase. Reference standards of Etoricoxib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => 2-Chloro-3-(dimethylamino)prop-2-en-1-iminiumchloride [catalogue_number] => PA 05 40530 [category_ids] => ,92, [chemical_name] => [weight] => 169.05 [form] => C5H10Cl2N2 [cas] => NA [pslug] => 2-chloro-3-dimethylamino-prop-2-en-1-iminiumchloride-pa0540530 [latest_product] => 0 [linkproducts] => 0 [offers_id] => 8 [offers_name] => Ready Stock [offers_status] => 1 [offers_start_date] => 2024-12-16 [offers_end_date] => 2024-12-31 [pageview] => 2 [offers_slug] => ready-stock [offers_product_id] => 35877 [offers_product_code] => PA 05 40530 [offers_master_id] => 8 [offer_percentage] => 20 % OFF [offers_product_main_cat] => Pharmaceutical Reference Standards )
Catalogue No.:PA 05 40530
CAS :
Molecular Formula : C5H10Cl2N2
Molecular Weight : 169.05
stdClass Object ( [pname] => 2-Chloro-1,3-bis(dimethylamino)trimethinium hexafluorophosphate [catalogue_number] => PA 05 40640 [category_ids] => ,92, [chemical_name] => [weight] => 306.62 [form] => C7H14ClF6N2P [cas] => 249561-98-6 [pslug] => 249561-98-6-2-chloro-1-3-bis-dimethylamino-trimethinium-hexafluorophosphate-pa0540640 [latest_product] => 0 [linkproducts] => 0 [offers_id] => 8 [offers_name] => Ready Stock [offers_status] => 1 [offers_start_date] => 2024-12-16 [offers_end_date] => 2024-12-31 [pageview] => 2 [offers_slug] => ready-stock [offers_product_id] => 35888 [offers_product_code] => PA 05 40640 [offers_master_id] => 8 [offer_percentage] => 20 % OFF [offers_product_main_cat] => Pharmaceutical Reference Standards )
Catalogue No.:PA 05 40640
Molecular Formula : C7H14ClF6N2P
Molecular Weight : 306.62
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
